The FDA has granted approval to olaparib (Lynparza®, AstraZeneca Pharmaceuticals) with abiraterone and either prednisone or prednisolone for treatment of deleterious or suspected deleterious breast cancer gene–mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as detected by an FDA-approved companion diagnostic test. Why it matters: "Current treatment options in the first-line setting of mCRPC mainly comprise next-generation hormonal agents (eg, abiraterone and enzal...